Cocrystal Pharma (COCP) 10-Q2024 Q3 Quarterly report

Filed: 13 Nov 24, 8:30am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: affinity, cease, Chairman, characterized, compound, conclusion, costly, cyberattack, delay, distribution, Dry, earlier, efficacy, enforcing, EUA, expressed, extent, flu, forced, geopolitical, growth, implied, industry, infringing, key, law, mg, molnupiravir, partially, PB, pledged, political, powder, preferred, pressure, privacy, prosecuting, protein, PSLRA, purified, rely, reproducible, RSU, scope, sequence, spending, strictly, substantial, substantially, tampering, toxicology, unable, unauthorized, uncontrollable, viable, wake

Removed: accumulated, acquire, Antidilutive, approve, book, chain, choice, classification, classify, commencing, contact, counterparty, covering, depreciable, depreciate, derivative, discovered, discussed, event, exchanged, expect, freestanding, governmental, indexed, inflation, inflationary, initiate, labor, largely, life, main, proceed, profile, progressing, publicly, put, raw, receipt, recession, require, requirement, revise, selection, settle, settleable, software, strategy, summary, supply, target, test, title, transferred, Ukraine, voted, working

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

COCP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Cocrystal Pharma, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, Sam Lee, certify, pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Sam Lee
Sam Lee
President and Co-Chief Executive Officer
(Principal Executive Officer)

Dated: November 13, 2024

In connection with the quarterly report of Cocrystal Pharma, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, James Martin, certify, pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James Martin
James Martin
Chief Financial Officer and Co-Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)

Dated: November 13, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.